These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 16154222)
1. Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. Costantino L; Gandolfi F; Tosi G; Rivasi F; Vandelli MA; Forni F J Control Release; 2005 Nov; 108(1):84-96. PubMed ID: 16154222 [TBL] [Abstract][Full Text] [Related]
2. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. Tosi G; Costantino L; Rivasi F; Ruozi B; Leo E; Vergoni AV; Tacchi R; Bertolini A; Vandelli MA; Forni F J Control Release; 2007 Sep; 122(1):1-9. PubMed ID: 17651855 [TBL] [Abstract][Full Text] [Related]
3. Nanoparticulate drug carriers based on hybrid poly(D,L-lactide-co-glycolide)-dendron structures. Costantino L; Gandolfi F; Bossy-Nobs L; Tosi G; Gurny R; Rivasi F; Vandelli MA; Forni F Biomaterials; 2006 Sep; 27(26):4635-45. PubMed ID: 16716395 [TBL] [Abstract][Full Text] [Related]
4. Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution. Tosi G; Vergoni AV; Ruozi B; Bondioli L; Badiali L; Rivasi F; Costantino L; Forni F; Vandelli MA J Control Release; 2010 Jul; 145(1):49-57. PubMed ID: 20338201 [TBL] [Abstract][Full Text] [Related]
5. Can leptin-derived sequence-modified nanoparticles be suitable tools for brain delivery? Tosi G; Badiali L; Ruozi B; Vergoni AV; Bondioli L; Ferrari A; Rivasi F; Forni F; Vandelli MA Nanomedicine (Lond); 2012 Mar; 7(3):365-82. PubMed ID: 21957863 [TBL] [Abstract][Full Text] [Related]
7. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Wang ZH; Wang ZY; Sun CS; Wang CY; Jiang TY; Wang SL Biomaterials; 2010 Feb; 31(5):908-15. PubMed ID: 19853292 [TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: preparation and in vitro evaluation. Yang A; Yang L; Liu W; Li Z; Xu H; Yang X Int J Pharm; 2007 Feb; 331(1):123-32. PubMed ID: 17097246 [TBL] [Abstract][Full Text] [Related]
9. Transport of saquinavir across human brain-microvascular endothelial cells by poly(lactide-co-glycolide) nanoparticles with surface poly-(γ-glutamic acid). Kuo YC; Yu HW Int J Pharm; 2011 Sep; 416(1):365-75. PubMed ID: 21736932 [TBL] [Abstract][Full Text] [Related]
10. On the design of in situ forming biodegradable parenteral depot systems based on insulin loaded dialkylaminoalkyl-amine-poly(vinyl alcohol)-g-poly(lactide-co-glycolide) nanoparticles. Packhaeuser CB; Kissel T J Control Release; 2007 Nov; 123(2):131-40. PubMed ID: 17854938 [TBL] [Abstract][Full Text] [Related]
11. Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 2. Cationic peptide vectors for brain delivery. Adenot M; Merida P; Lahana R Chemotherapy; 2007; 53(1):73-6. PubMed ID: 17202815 [TBL] [Abstract][Full Text] [Related]
12. Drug delivery to the CNS and polymeric nanoparticulate carriers. Costantino L Future Med Chem; 2010 Nov; 2(11):1681-701. PubMed ID: 21428839 [TBL] [Abstract][Full Text] [Related]
13. Surfactants, not size or zeta-potential influence blood-brain barrier passage of polymeric nanoparticles. Voigt N; Henrich-Noack P; Kockentiedt S; Hintz W; Tomas J; Sabel BA Eur J Pharm Biopharm; 2014 May; 87(1):19-29. PubMed ID: 24607790 [TBL] [Abstract][Full Text] [Related]
14. Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier. Lu W; Tan YZ; Hu KL; Jiang XG Int J Pharm; 2005 May; 295(1-2):247-60. PubMed ID: 15848009 [TBL] [Abstract][Full Text] [Related]
15. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Gelperina S; Maksimenko O; Khalansky A; Vanchugova L; Shipulo E; Abbasova K; Berdiev R; Wohlfart S; Chepurnova N; Kreuter J Eur J Pharm Biopharm; 2010 Feb; 74(2):157-63. PubMed ID: 19755158 [TBL] [Abstract][Full Text] [Related]
16. Transport of Poly(n-butylcyano-acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity. Rempe R; Cramer S; Hüwel S; Galla HJ Biochem Biophys Res Commun; 2011 Mar; 406(1):64-9. PubMed ID: 21295549 [TBL] [Abstract][Full Text] [Related]
17. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease. Hu K; Shi Y; Jiang W; Han J; Huang S; Jiang X Int J Pharm; 2011 Aug; 415(1-2):273-83. PubMed ID: 21651967 [TBL] [Abstract][Full Text] [Related]
18. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Liu L; Guo K; Lu J; Venkatraman SS; Luo D; Ng KC; Ling EA; Moochhala S; Yang YY Biomaterials; 2008 Apr; 29(10):1509-17. PubMed ID: 18155137 [TBL] [Abstract][Full Text] [Related]
19. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier. Tosi G; Fano RA; Bondioli L; Badiali L; Benassi R; Rivasi F; Ruozi B; Forni F; Vandelli MA Nanomedicine (Lond); 2011 Apr; 6(3):423-36. PubMed ID: 21542682 [TBL] [Abstract][Full Text] [Related]
20. Brain delivery and systemic effect of cationic albumin conjugated PLGA nanoparticles. Xu F; Lu W; Wu H; Fan L; Gao X; Jiang X J Drug Target; 2009 Jul; 17(6):423-34. PubMed ID: 19527113 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]